Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer
This study establishes MLKL as a master regulator of anti-tumor immunity in OC, driving chemokine-mediated immune cell recruitment and TME reprogramming. The novel NecropImmScore is a multifaceted biomarker that effectively predicts prognosis, immunotherapy response, BRCA1 deficiency, and chemosensitivity, offering significant potential for guiding precision therapeutic strategies in OC.
Authors
- Shaohua Xu (ORCID: https://orcid.org/0000-0001-9810-1325)
- Fangfang Xu (ORCID: https://orcid.org/0000-0001-7598-0136)
- Shufeng Kang
Institutions
- Shanghai First Maternity and Infant Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1007/s00262-025-04192-z
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China